INSPIRED Symposium Part 5: Expanding the Use of CAR T cells in Children and Young Adults

Chimeric antigen receptor (CAR) T cell therapies have shown remarkable efficacy in the treatment of relapsed/refractory (r/r) B cell malignancies, including in children and young adults with B cell acute lymphoblastic leukemia (ALL).1-7 However, the efficacy that CAR T cell therapies have shown in B cell malignancies has not yet translated to equivalent success in non-B cell hematologic malignancies, central nervous system (CNS) tumors, and non-CNS solid tumors. Emerging strategies to enhance CAR T cell efficacy and safety for other malignancies have begun to show promise in early-phase clinical trials.

Source: Biology of Blood and Marrow Transplantation - April 6, 2024 Category: Hematology Authors: Aimee C. Talleur, Vanessa A. Fabrizio, Richard Aplenc, Stephan A. Grupp, Crystal Mackall, Robbie Majzner, Rosa Nguyen, Rayne Rouce, Amy Moskop, Kevin O. McNerney Source Type: research